These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Price type key:
Federal Supply Schedule (FSS): generally available to all Federal Govt agencies /
'BIG4' prices: VA, DoD, Public Health & Coast Guard only /
National Contracts (NC): Available to specific agencies
33342-0248 Market Analysis and Financial Projection
Repaglinide (NDC 33342-0248), an oral antidiabetic medication manufactured by Macleods Pharmaceuticals, is a key player in the type 2 diabetes market. Market trends and pricing dynamics for this drug reflect broader industry forces, including rising diabetes prevalence, competitive pressures, and evolving treatment guidelines.
Market Overview and Growth Projections
Current Market Size: The global Repaglinide market was valued at $1.5 billion in 2024, with projections reaching $2.3 billion by 2033, growing at a 5.2% CAGR[11]. Another study cites a broader market (including APIs) at $85 billion in 2023, expected to hit $109 billion by 2031[9].
Growth Drivers:
Rising global prevalence of type 2 diabetes, affecting over 537 million adults (2021), projected to reach 783 million by 2045[16].
Repaglinide’s rapid onset of action (ideal for postprandial glucose control)[9].
Expansion of generic versions, improving accessibility in developing markets[14].
Pricing Trends
Retail Pricing: The average cost for a 100-tablet bottle of Repaglinide 0.5 mg is $56.50 (cash price), though prices vary by pharmacy and insurance[17].
Wholesale Trends: While NADAC pricing data for Repaglinide isn’t directly available, comparable drugs by Macleods (e.g., Amlodipine/Valsartan) show stable wholesale pricing at ~$0.45 per unit[3], suggesting similar cost structures for Repaglinide.
Market Segmentation
By Product:
Above 99% purity: Preferred for pharmaceutical use due to stringent regulatory standards[14].
Tablets vs. Capsules: Tablets dominate, comprising 80% of formulations[10].
By Region:
Asia-Pacific: Leads production and consumption due to high diabetes rates and manufacturing hubs in India/China[14].
North America: Accounts for 63% of diabetes drug sales globally, driven by higher drug prices[5].
Competitive Landscape
Key Players: Macleods Pharmaceuticals (generic leader), Novo Nordisk, Sun Pharma, and Boehringer Ingelheim[14][16].
Generic Competition: Repaglinide’s patent expiry has led to price erosion, with generics capturing 70% of the market[9][16].
Challenges and Restraints
Alternative Therapies: Competition from metformin, GLP-1 agonists, and SGLT2 inhibitors limits Repaglinide’s market share[11].
Side Effects: Hypoglycemia risk reduces its preference as a first-line treatment[16].
Price Projections
Short-Term (2025–2026): Stable pricing due to established generics and NADAC benchmarking (~$0.50–$1.60 per tablet)[17].
Long-Term (2030+): Prices may decline by 2–3% annually as newer therapies and biosimilars enter the market[9][14].
Strategic Insights
Emerging Markets: India and China will drive volume growth, offsetting price declines in mature markets[14].
Regulatory Impact: FDA/EMA quality mandates may increase production costs, favoring larger manufacturers[14].
Quote on Market Dynamics:
“The rise of generics has democratized access to Repaglinide, but innovation in delivery systems is critical for long-term competitiveness.” – DrugPatentWatch Analysis[2].
Key Takeaways
Repaglinide remains a cost-effective option for postprandial glucose management.
Generic dominance and regional healthcare expansion shape pricing.
Market growth hinges on diabetes epidemiology, not breakthrough innovation.
For real-time pricing, pharmacies and insurers should monitor NADAC updates and Medicaid reimbursement policies[3][17].
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
